Janssen Archives

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […]

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2016

How is European Immuno-Oncology fighting Blood Cancer?

From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field. The 58th ASH annual meeting is wrapping up today, after the best companies […]

December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Jun 2016

12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why? It’s where one of the biggest oncology events happens – the ASCO Annual Meeting 2016. Shortly after the AACR annual meeting (with presentations from several European Biotechs), it’s time for the ASCO annual meeting. Hosted by the American Society of Clinical […]

June 8, 2016 - 7 minutesmins - By Denise Neves Gameiro

embl microbiome janssen eligo enterome jj inra therapeutics crohns

News and Trends 7 Jan 2016

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

The Janssen Human Microbiome Institute, the French National Institute for Agricultural Research (INRA) and Johnson & Johnson Innovation AND Takeda are signing up to collaborate with the Paris biotech Enterome to help accelerate Microbiomics research into Crohn’s Disease. The collaboration is based on initial findings by the INRA showing that some commensal (symbiotic) bacteria elicit […]

January 7, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Aug 2015

It’s proven: The (Almost) Universal Flu Vaccine is Possible!

The foundation stone was laid: A Dutch-American collaboration published in Science the first proof of concept that we could replace the seasonal flu shots with a vaccine that recognizes almost every subtype. The influenza virus is incredibly variable. A yearly refreshment of flu shots is necessary to provide a moderate protection against it, and subtypes […]

August 26, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 15 May 2015

European Union supports Bavarian Nordic to cure Ebola

Bavarian Nordic has been granted €50M loan from the European Investment Bank (EIB) to support the companies’ pipeline including novel vaccines against Ebola and other infectious diseases as well as cancer immunotherapies. The loan is a three-to-five year bullet loan with fixed or variable interest payment. Bavarian Nordic has up to 18 months to draw […]

May 15, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 22 Oct 2014

New Treatment against critic Leukemia Approved In Europe

Janssen’s Imbruvica (ibrutinib), the once-daily oral Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Europe as a treatment for two blood cancers. The drug has been ratified by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia. The therapy functions block BTK, a protein that […]

October 22, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us